Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Antisense Therapeutics reports data from interim analysis of ATL-1103

Dec. 30, 2013

Resverlogix completes enrollment in phase II trial of RVX-208

Dec. 30, 2013

FDA issues CRL for Actavis' progestin-only transdermal contraceptive patch

Dec. 27, 2013

WARF prepares new VDR ligands for bone and other disorders

Dec. 27, 2013

FDA delays action on Vascepa sNDA

Dec. 27, 2013

Amgen reports topline results from 52-week phase III DESCARTES study

Dec. 27, 2013

Eli Lilly and Boehringer Ingelheim submit NDA to FDA for new insulin glargine product

Dec. 24, 2013

Tenelia receives approval for partial change as combination therapy

Dec. 23, 2013

AstraZeneca to acquire Bristol-Myers Squibb's diabetes alliance assets

Dec. 20, 2013

Euroscreen begins phase I trial of ESN-364

Dec. 20, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...